The S-1 filing progression signals an imminent dilutive offering. Watch for the EFFECT notice (Form EFFECT) which will confirm SEC clearance and trigger the pricing. Track any concurrent 8-K for underwriting agreement and final pricing terms.
Executive Summary
AEON Biopharma filed Amendment No. 1 to its S-1 registration statement, a procedural exhibits-only update to increase the proposed maximum aggregate offering price of the Five-Year Milestone Warrants to 115% of the assumed IPO price ($16.5M vs $14.4M previously) and pay the incremental $298 fee. The total registered offering amount remains $45.3M against an $18M market cap, signaling a highly dilutive public offering that is progressing toward effectiveness. This is a pre-revenue clinical-stage biotech with a checkered history of capital raises and poor historical stock performance.
Key Facts
- Total offering amount registered is $45,281,250 across common stock and milestone warrants, representing ~2.5x the current $18M market cap
- Five-Year Milestone Warrants' underlying stock registered at 115% of assumed public offering price, up from 100% in prior filing
- The amendment is pre-effective and moves the S-1 toward SEC clearance, bringing a dilutive offering closer to execution
- Incremental registration fee paid is only $297.78, but the offering size is material relative to existing equity base
- The company has a history of multiple warrant issuances, convertible notes, and capital raises (Nov 2025, Dec 2025, and prior rounds)
Financial Impact
Potential dilution of up to ~$45.3M in new securities vs $18M current market cap; exact dilution depends on offering price and number of shares, but could exceed 100% of current shares outstanding
Risk Factors
- Massive shareholder dilution upon effectiveness of the S-1 (offering up to 2.5x market cap)
- Pre-revenue clinical-stage company with no approved products and ongoing cash burn
- History of multiple dilutive financings (warrants, convertible notes) that complicate capital structure
- Dependence on Daewoong Pharmaceutical license for core technology; any disruption would be existential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (AEON) — Batch item 1 | 0001104659-26-082167 |
| Document: tm2615250d6_ex-filingfees.htm | 0001104659-26-082167 |
| Document: 0001104659-26-082167-index-headers.html | 0001104659-26-082167 |
| Document: 0001104659-26-082167-index.html | 0001104659-26-082167 |
| Document: 0001104659-26-082167.txt | 0001104659-26-082167 |
| S-1/A Filing (AEON) — Batch item 6 | 0001104659-26-082167 |
| Document: tm2615250d6_ex-filingfees.htm | 0001104659-26-082167 |
| Document: 0001104659-26-082167-index-headers.html | 0001104659-26-082167 |
| Document: 0001104659-26-082167-index.html | 0001104659-26-082167 |
| Document: 0001104659-26-082167.txt | 0001104659-26-082167 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | $0.2350 | awaiting T+5 | — | $0.2473 (+5.23%) |
Oct 23, 2026 3d ago | 8-K | $0.2399 | awaiting T+5 | — | $0.2473 (+3.08%) |
Sep 30, 2026 27d ago | 8-K | $0.3000 $0.3110 | ▲ +3.67% | ▲ +1.75% | $0.2473 (−17.57%) |
Aug 21, 2026 9w ago | 3 | $0.1974 $0.2959 | ▲ +49.90% | ▲ +49.43% | $0.2473 (+25.28%) |
Aug 19, 2026 9w ago | Press Release | $0.1980 $0.2515 | ▲ +27.02% | ▲ +27.41% | $0.2473 (+24.90%) |
Aug 12, 2026 10w ago | Press Release | $0.2706 $0.1931 | ▼ −28.64% | ▼ −26.68% | $0.2473 (−8.61%) |
Jul 23, 2026 13w ago | 8-K | $0.2507 $0.2552 | ▼ −1.79% | ▼ −1.42% | $0.2473 (+1.36%) |
Jul 15, 2026 14w ago | 8-K | $0.2974 $0.2600 | ▲ +12.58% | ▲ +10.91% | $0.2473 (+16.85%) |
Jul 15, 2026 14w ago | 424B4 | $0.2997 $0.2752 | ▲ +8.17% | ▲ +7.19% | $0.2473 (+17.48%) |
Jul 14, 2026 15w ago | EFFECT | $0.3570 $0.2890 | ▲ +19.05% | ▲ +17.75% | $0.2473 (+30.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers